Depression is estimated to affect nearly 340 million people worldwide and 18 million people in the US at any given time [1-2], making it the third most costly and disabling illness in the US [3-8]. By the year 2020, it is predicted that depressive illness will be the second leading cause of disability worldwide . Duloxetine is a potent and balanced inhibitor of the reuptake of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE). In-vitro and in-vivo it is used to treat depression, diabetic peripheral neuropathic pain and stress urinary incontinence [10- 15]. Duloxetine is eliminated primarily in the urine after being extensively metabolized in the liver by oxidative enzymes, principally cytochrome P-450 (CYP) isoenzyme 2D6 and to a laser extent, CYPIAZ. Its elimination is primarily through hepatic metabolism, and biotransformation pathways involve oxidation of the napthyl ring, followed by conjugation and further oxidation. Major metabolities found in plasma include 4- hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate.
Journal: TechConnect Briefs
Volume: 2, Nanotechnology 2009: Life Sciences, Medicine, Diagnostics, Bio Materials and Composites
Published: May 3, 2009
Pages: 85 - 87
Industry sector: Medical & Biotech
Topicss: Biomaterials, Materials for Drug & Gene Delivery